Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Rumors about compounded semaglutide discontinuation circulate frequently among patients seeking weight loss medication. The FDA has not issued a blanket ban on semaglutide compounding; however, regulatory oversight of 503A pharmacies has intensified over the past two years. PlexusDx partners exclusively with licensed 503A compounding pharmacies to deliver semaglutide injections that meet pharmaceutical standards across all 50 states.

What's Actually Happening With Compounded Semaglutide Availability

The FDA has not discontinued compounded semaglutide entirely, but the agency has increased inspections and enforcement actions against certain compounding facilities. These regulatory efforts focus on pharmacies lacking proper licensing, quality control, or sterility protocols—not on 503A-licensed operations. Legitimate compounding remains a legal pathway for patients unable to access branded medications due to cost, supply shortages, or insurance barriers.

PlexusDx sources semaglutide exclusively from licensed 503A compounding pharmacies that maintain strict quality, potency, and sterility standards. Each compound undergoes verification to ensure consistency and safety before shipment. This distinction between compliant 503A pharmacies and unlicensed or 503B facilities is critical for patient protection and medication efficacy.

Licensed 503A Pharmacies vs. Unlicensed Compounding Sources

A 503A compounding pharmacy is a traditional pharmacy licensed by individual states that prepares customized medications under a pharmacist's supervision. These facilities are subject to state board oversight, inspections, and federal regulations under the FDA's jurisdiction. A 503B outsourcing facility operates under different rules and primarily supplies medications to healthcare institutions—not individual patients directly.

PlexusDx exclusively partners with state-licensed 503A compounding pharmacies because they maintain accountability to state pharmacy boards, undergo routine inspections, and adhere to USP standards for sterility, testing, and labeling. Patients who purchase from unlicensed or unverified sources risk receiving contaminated, impotent, or counterfeit medications. When choosing a compounded GLP-1 provider, confirmation of 503A licensing is the first safety checkpoint.

Why Compounded Semaglutide Remains an Important Treatment Option

Brand-name Ozempic and Wegovy have experienced repeated supply shortages since 2022, leaving millions of patients unable to access the medication. Compounded semaglutide fills this access gap by offering the same active pharmaceutical ingredient prepared in licensed facilities at a lower cost. For patients with insurance coverage gaps, high deductibles, or prior authorization denials, compounded options have proven essential.

Clinical evidence supports the safety and efficacy of compounded semaglutide when sourced from licensed pharmacies. A 2023 observational study examining compounded GLP-1 outcomes found similar weight loss trajectories and side effect profiles compared to brand-name formulations. PlexusDx's compounded semaglutide injection starts at $149 per month with flat pricing regardless of dose escalation—eliminating surprise cost increases as treatment progresses.

How PlexusDx Ensures Quality and Safety in Compounded Medications

PlexusDx verifies every compounding pharmacy partner's state licensure, facility inspections, and quality certifications before establishing a relationship. All semaglutide compounds are prepared in facilities that comply with United States Pharmacopeia (USP) standards for sterility, potency testing, and container integrity. Patients receive detailed documentation of their medication's source and preparation date.

Beyond sourcing, PlexusDx pairs compounded semaglutide with personalized support including nurse consultations, dose optimization guidance, and side effect management strategies. Optional Precision Peptide Genetic Testing ($99 add-on after month one) maps 14 metabolic pathways and 49 peptide-related variants—including GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313—to predict individual response patterns. This genetic insight helps clinicians tailor therapy, improving outcomes and reducing trial-and-error dosing.

Alternative GLP-1 Compounds if Semaglutide Becomes Unavailable

PlexusDx offers multiple compounded GLP-1 options beyond semaglutide to ensure treatment continuity. Compounded tirzepatide injection (dual GIP/GLP-1 receptor agonist) starts at $249 per month and often produces faster, more robust weight loss in patients who experience plateaus with semaglutide alone. For patients preferring oral administration, oral semaglutide ($249/mo) and oral tirzepatide ($279/mo) provide convenient alternatives.

The GLP-Squared injection protocol ($249/mo) combines semaglutide and tirzepatide in a single weekly formulation, offering synergistic pathway activation for patients requiring maximal pharmacological support. Regardless of which compound a patient uses, PlexusDx's flat monthly pricing structure—with no dose-based escalations—ensures transparent, predictable costs throughout the treatment journey.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is the FDA banning all compounded semaglutide?

No. The FDA has not issued a blanket discontinuation of compounded semaglutide. The agency has increased oversight of compounding pharmacies, targeting facilities lacking proper licensure or quality control. Licensed 503A pharmacies continue operating legally and serving patients nationwide. PlexusDx sources exclusively from verified 503A-licensed facilities.

How do I know if my compounded semaglutide is safe?

Verify that your pharmacy is state-licensed as a 503A compounding pharmacy (not a 503B outsourcing facility) and confirm it has passed recent FDA and state board inspections. Ask for documentation of sterility testing, potency assays, and USP compliance. PlexusDx provides transparency on all pharmacy partners and their licensing status.

What makes PlexusDx compounded semaglutide different from other providers?

PlexusDx partners exclusively with licensed 503A compounding pharmacies, offers flat pricing ($149/mo) regardless of dose level, requires no insurance, is HSA/FSA-eligible, and provides optional genetic testing to personalize treatment. All 50 states are served with nurse-supported consultations included.

Is compounded semaglutide as effective as brand-name Ozempic or Wegovy?

Clinical evidence indicates compounded semaglutide containing the same active ingredient produces comparable weight loss and metabolic outcomes when sourced from licensed pharmacies. A 2023 observational cohort found similar efficacy and adverse event profiles between compounded and brand formulations, though individual responses vary based on metabolism and genetics.

Can genetic testing help determine if compounded semaglutide will work for me?

Yes. PlexusDx's Precision Peptide Genetic Test ($99 add-on) identifies variants in GLP1R, GIPR, FTO, and MC4R pathways that predict individual medication response. Patients with certain genetic profiles may respond better to tirzepatide, oral formulations, or combination protocols, allowing clinicians to optimize therapy from the start rather than through trial-and-error.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves